Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Novel Researches on Upper Tract Urothelial Carcinoma
share announcement

Novel Researches on Upper Tract Urothelial Carcinoma

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nephrology & Urology".

Deadline for manuscript submissions: closed (25 December 2019) | Viewed by 7335

Special Issue Editors

Dr. Evanguelos Xylinas

E-Mail Website1 Website2
Guest Editor
Paris Descartes University, Cochin Hosp, AP HP, Dept Urol, 27 Rue Faubourg St Jacques, F-75014 Paris, France
Interests: uro-oncology; urothelial carcinoma
Dr. Idir Ouzaid

E-Mail Website
Guest Editor
Paris Diderot University, Paris, France
Interests: uro-oncology; kidney cancer; prostate cancer; robotics

Special Issue Information

Dear Colleagues,

Upper tract urothelial carcinoma (UTUC) is relatively rare among urothelial cancers, with an incidence of about two cases per 100,000 person-years. Despite earlier diagnosis, non-invasive surgical managements, and the increased use of perioperative chemotherapy, UTUC is associated with poor oncologic outcomes. According to the current guidelines, the gold standard treatment for UTUC is radical nephroureterectomy (RNU) with bladder cuff resection. Methods of surgery and ancillary neoadjuvant or adjuvant therapy may impact patient outcomes. In this Special Issue, we will review current studies and opinions on questions about the surgical and medical management of UTUC.

Dr. Evanguelos Xylinas
Dr. Idir Ouzaid
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Upper tract urothelial carcinoma
  • Mini-invasive surgery
  • Predictive tools
  • Perioperative systemic treatments

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

16 pages, 904 KiB  
Review
Lymphadenectomy for Upper Tract Urothelial Carcinoma: A Systematic Review
by Igor Duquesne, Idir Ouzaid, Yohann Loriot, Marco Moschini and Evanguelos Xylinas
J. Clin. Med. 2019, 8(8), 1190; https://doi.org/10.3390/jcm8081190 - 08 Aug 2019
Cited by 15 | Viewed by 3398
Abstract
Background: The role of lymphonodal dissection during surgery for a tumor of the urinary tract remains controversial. Objective: To analyze anatomical bases of lymphonodal dissection in tumors of the upper urinary tract and analyze its impact on survival, recurrence, and staging. Acquisition of [...] Read more.
Background: The role of lymphonodal dissection during surgery for a tumor of the urinary tract remains controversial. Objective: To analyze anatomical bases of lymphonodal dissection in tumors of the upper urinary tract and analyze its impact on survival, recurrence, and staging. Acquisition of data: A web-based search for scientific articles using Medline/Pubmed was carried out to identify and analyze articles on the practice and the role of lymphonodal dissection in this indication. Data Synthesis: The lymphatic drainage of the upper urinary tract has rarely been studied and is poorly understood. The lymphonodal metastatic extension is the most common extension in upper urinary tract urothelial carcinoma. Lymphnode invasion is a clear independent poor prognostic factor. Therefore, it seems legitimate to offer an extended lymphonodal dissection to patients undergoing surgery to cure these tumors. When lymphnodes dissection respects clear anatomical principles based on the location of the primary tumor and its extension, it improves both survival and recurrence rates. This result could be secondary to the treatment of subclinical metastatic disease. Conclusion: An extended lymphadenectomy during surgery for upper urinary tract urothelial carcinoma following strict anatomical pattern improves staging with a highly probable therapeutic benefit. Full article
(This article belongs to the Special Issue Novel Researches on Upper Tract Urothelial Carcinoma)
►▼ Show Figures

Figure 1

12 pages, 1968 KiB  
Review
Intravesical Chemotherapy after Radical Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma: A Systematic Review and Network Meta-Analysis
by Sang Hyun Yoo, Chang Wook Jeong, Cheol Kwak, Hyeon Hoe Kim, Min Soo Choo and Ja Hyeon Ku
J. Clin. Med. 2019, 8(7), 1059; https://doi.org/10.3390/jcm8071059 - 19 Jul 2019
Cited by 11 | Viewed by 3642
Abstract
The aim of this study was to determine the prophylactic effect of intravesical chemotherapy. Furthermore, it aimed to compare the efficacy of regimens on the prevention of bladder recurrence, after nephroureterectomy, for upper tract urothelial carcinoma by systematic review and network meta-analysis. A [...] Read more.
The aim of this study was to determine the prophylactic effect of intravesical chemotherapy. Furthermore, it aimed to compare the efficacy of regimens on the prevention of bladder recurrence, after nephroureterectomy, for upper tract urothelial carcinoma by systematic review and network meta-analysis. A comprehensive literature search was conducted to search for studies published before 22 December 2016 using PubMed, Embase, and Scopus. All studies comparing nephroureterectomy alone with prophylactic intravesical chemotherapy after nephroureterectomy were included. The primary outcome was intravesical recurrence-free survival rate. In addition, we conducted indirect comparisons among regimens using network meta-analysis, as well as three randomized controlled trials (RCTs) on multicenter setting, and one large retrospective study with a total of 532 patients were analyzed. The pooled hazard ratio (HR) of bladder recurrence was 0.54 (95% CI: 0.38–0.76) in intravesical instillation patients. On network meta-analysis, pirarubicin was ranked the most effective regimen, while maintenance therapy of mitomycin C (MMC) with Ara-C and induction therapy of MMC were ranked as the second and third most effective regimens, respectively. Our study demonstrates that intravesical chemotherapy can prevent bladder recurrence in patients with upper tract urothelial carcinoma after nephroureterectomy. It also suggests that a single instillation of pirarubicin is the most efficacious intravesical regimen. Full article
(This article belongs to the Special Issue Novel Researches on Upper Tract Urothelial Carcinoma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop